Paladin Labs Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Montreal Quebec Canada (1983)
Status: Acquired by Endo Pharmaceuticals (2014) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial
2010
NCT01067443
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Paladin Laboratories Inc | Paladin Labs Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

tacrolimus (prograf) (2 trials)

Drugs in Phase 3 Trials (5)

Key: Paladin Labs (1) Acquired (4)

acetaminophen (tylenol) (2 trials)

apomorphine (apokyn) (1 trial)

davunetide (3 trials)

tramadol (Ultram) (15 trials)

trazodone (desyrel) (5 trials)

Drugs in Phase 2 Trials (3)

amphotericin b (fungizone) (1 trial)

miltefosine (impavido) (1 trial)

sodium stibogluconate (Pentostam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 2)

Leishmaniasis, Visceral (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 9